# Sexually Transmitted Disease Surveillance 1998

**Division of STD Prevention September 1999** 

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for HIV, STD, and TB Prevention
Division of STD Prevention
Atlanta, Georgia 30333

Centers for Disease Control and PreventionJeffrey P. Koplan, M.D., M.P.H.  Director
National Center for HIV, STD, and TB PreventionHelene D. Gayle, M.D., M.P.H. Director
Division of STD PreventionJudith N. Wasserheit, M.D., M.P.H.  Director
Epidemiology and Surveillance BranchMichael E. St. Louis, M.D. <i>Chief</i>
Surveillance and Special Studies SectionWilliam C. Levine, M.D., M.Sc.  Chief
Statistics and Data Management BranchRussell H. Roegner, Ph.D. Chief

Melinda L. Flock, M.S.P.H.

Deputy Chief

# **Copyright Information**

All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

### **Suggested Citation**

Division of STD Prevention. Sexually Transmitted Disease Surveillance, 1998. Department of Health and Human Services, Atlanta: Centers for Disease Control and Prevention (CDC), September 1999.

Copies can be obtained from the Office of Communications, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-06, Atlanta, Georgia 30333.

The report is also available by Internet via the CDC home page at: http://www.cdc.gov/nchstp/dstd/Stats\_Trends/1998\_Surv\_Rpt\_main\_pg.htm

### **Foreword**

"STDs are hidden epidemics of enormous health and economic consequence in the United States. They are hidden because many Americans are reluctant to address sexual health issues in an open way and because of the biologic and social characteristics of these diseases. All Americans have an interest in STD prevention because all communities are impacted by STDs and all individuals directly or indirectly pay for the costs of these diseases. STDs are public health problems that lack easy solutions because they are rooted in human behavior and fundamental societal problems. Indeed, there are many obstacles to effective prevention efforts. The first hurdle will be to confront the reluctance of American society to openly confront issues surrounding sexuality and STDs. Despite the barriers, there are existing individual- and community-based interventions that are effective and can be implemented immediately. That is why a multifaceted approach is necessary to both the individual and community levels.

To successfully prevent STDs, many stakeholders need to redefine their mission, refocus their efforts, modify how they deliver services, and accept new responsibilities. In this process, strong leadership, innovative thinking, partnerships, and adequate resources will be required. The additional investment required to effectively prevent STDs may be considerable, but it is negligible when compared with the likely return on the investment. The process of preventing STDs must be a collaborative one. No one agency, organization, or sector can effectively do it alone; all members of the community must do their part. A successful national initiative to confront and prevent STDs requires widespread public awareness and participation and bold national leadership from the highest levels"<sup>1</sup>.

<sup>&</sup>lt;sup>1</sup>Concluding statement from the Institute of Medicine's Summary Report, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, National Academy Press, Washington, D.C., 1997, p.43.

### **Preface**

Sexually Transmitted Disease Surveillance, 1998 presents statistics and trends of sexually transmitted diseases (STDs) in the United States through 1998. This annual publication is intended as a reference document for policy makers, program managers, health planners, researchers, and others who are concerned with the public health implications of these diseases. The figures and tables in this edition supersede those in earlier publications of these data.

The surveillance information in this report is based on the following sources of data: (1) case reports from the STD project areas; (2) prevalence data from the Regional Infertility Prevention Projects, STD project areas, the U.S. Job Corps, and Jail STD Prevalence Monitoring Projects; (3) sentinel surveillance of gonococcal antimicrobial resistance from the Gonococcal Isolate Surveillance Project; and (4) national sample surveys implemented by federal and private organizations.

The STD surveillance systems operated by state and local STD control programs, which provide the case report data, are the sources of most of the information in this publication. These systems are an integral part of program management at all levels of STD prevention and control in the United States.

Sexually Transmitted Disease Surveillance, 1998 consists of four parts. The **National Profile** contains figures that provide an overview of STD morbidity in the United States. The accompanying text identifies major findings and trends for selected STDs. The **Special Focus Profiles** contain figures and text describing STDs in selected subgroups and populations that are a focus of national and state prevention efforts. The **Detailed Tables** provide statistical information about STDs at the state, county, city, and national levels. The **Appendix** includes the sources and limitations of the data used to produce this report; Table A1 displays progress made toward Healthy People 2000 Priority Area 19, Objectives 19.1-19.8, on Sexually Transmitted Diseases; and Figures A1-A3 show progress made by states in converting from hardcopy aggregate reporting to electronic line-listed data submissions.

Selected figures and tables in this document include a reference point that is used to monitor progress toward some of the Healthy People 2000 (HP2000) national health status objectives for STDs<sup>1</sup>. The original HP2000 health status objectives were developed in 1989 and revised in 1995. The revisions are used as reference points in this edition of Sexually Transmitted Disease Surveillance, 1998.

Any comments and suggestions that would improve the usefulness of future publications are appreciated and should be sent to Director, Division of STD Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-02, Atlanta, Georgia, 30333.

<sup>&</sup>lt;sup>1</sup>Department of Health and Human Services. *Healthy People 2000: Midcourse Review and 1995 Revisions*. U.S. Department of Health and Human Services, Public Health Service, U.S. Government Printing Office, Washington, D.C., 1995.

### **Acknowledgments**

Publication of this report would not have been possible without the contributions of the State and Territorial Health Departments and the Sexually Transmitted Disease Control Programs, who provided state and local surveillance data to the Centers for Disease Control and Prevention.

This report was prepared by the following staff members of the Division of STD Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention: Charles Akers, Susan Bradley, Jim Braxton, Sharon Clanton, Darlene Davis, Lyn Finelli, LaZetta Grier, Alesia Jester Harvey, Sharon Hixon, Kathleen Hutchins, Kristen Mertz, Debra Mosure, Raymond Ransom, LuEtta Schneider, Maya Sternberg, Emmett Swint, Susan Wang and Akbar Zaidi.

### **Dedication**

We dedicate this volume to our colleague and friend, Russ Roegner. After 3 years as the Chief of the Statistics and Data Management Branch, Dr. Roegner is moving on to Washington, D.C. He has been an outstanding leader and dedicated member of the team producing this report. We wish him the best in the years to come.

### **Contents**

Foreword
Preface
acknowledgments
igures in the National Profile
additional Figures for the Special Focus Profilesxii
ables in the National Profilexiv
Geographic Divisions of the United Statesxvii
National Overview of Sexually Transmitted Diseases, 1998
National Profile
Introduction3Chlamydia5Gonorrhea13Syphilis23Other Sexually Transmitted Diseases33
Special Focus Profiles
Introduction37STDs in Women and Infants39STDs in Adolescents and Young Adults49STDs in Minorities55STDs in Persons Entering Corrections Facilities61STDs in the South65
Detailed Tables
Summary Tables69Chlamydia Tables72Gonorrhea Tables82Syphilis Tables92Chancroid Tables114
Appendix
Sources and Limitations of Data

# **Figures in the National Profile**

Chiamydia	
Figure 1.	Chlamydia — Number of states that require reporting of <b>Chlamydia trachomatis</b> infections: United States, 1987–1998
Figure 2.	Chlamydia — Reported rates: United States, 1984–1998
Figure 3.	Chlamydia — Rates by state: United States and outlying areas, 1998 8
Figure 4.	Chlamydia — Rates by region: United States, 1984–19988
Figure 5.	Chlamydia — Rates in selected U.S. cities of >200,000 population, 1984–1998
Figure 6.	Chlamydia — Rates by gender: United States, 1984–1998 9
Figure 7.	Chlamydia — Age- and gender-specific rates: United States, 1998 10
Figure 8.	Chlamydia — Positivity among women tested in family planning clinics by state: Region X, 1988–1998
Figure 9.	Chlamydia — Positivity among 15-24 year old women tested in family planning clinics by state, 1998
Figure 10.	Chlamydia — Trends in positivity among 15-44 year old women tested in family planning clinics by HHS regions, 1988–1998
Gonorrhea	
Figure 11.	Gonorrhea — Reported rates: United States, 1970–1998 and the Healthy People year 2000 objective
Figure 12.	Gonorrhea — Rates by state: United States and outlying areas, 1998 16
Figure 13.	Gonorrhea — Rates by region: United States, 1981–1998 and the Healthy People year 2000 objective
Figure 14.	Gonorrhea — Rates in selected U.S. cities of >200,000 population, 1981–1998 and the Healthy People year 2000 objective
Figure 15.	Gonorrhea — Rates by gender: United States, 1981–1998 and the Healthy People year 2000 objective
Figure 16.	Gonorrhea — Rates by race and ethnicity: United States, 1981–1998 and the Healthy People year 2000 objective
Figure 17.	Gonorrhea — Age- and gender-specific rates: United States, 1998 19
Figure 18.	Gonorrhea — Positivity among 15-24 year old women tested in family planning clinics by state, 1998
Figure 19.	Gonococcal Isolate Surveillance Project (GISP) — Location of participating clinics and regional laboratories: United States, 1998 20
Figure 20.	Gonococcal Isolate Surveillance Project (GISP) — Trends in plasmid-mediated resistance to penicillin and tetracycline, 1988–199820
Figure 21.	Gonococcal Isolate Surveillance Project (GISP) — Trends in chromosomally mediated resistance to penicillin and tetracycline, 1988–1998 21
Figure 22.	Gonococcal Isolate Surveillance Project (GISP) — Prevalence of Neisseria gonorrhoeae with decreased susceptibility or resistance to ciprofloxacin, 1990–1998
Figure 23.	Gonococcal Isolate Surveillance Project (GISP) — Proportion of men with gonorrhea who had a previous gonorrhea infection within the past year, 1992–1998

Figure 24.	Gonococcal Isolate Surveillance Project (GISP) — Percent of <i>Neisseria</i> gonorrhoeae isolates obtained from men who have sex with men for STD clinics in nine cities, 1994, 1996 and 1998	
Syphilis		
Figure 25.	Syphilis — Reported cases by stage of illness: United States, 1941–1998 26	
Figure 26.	Primary and secondary syphilis — Reported rates: United States, 1970–1998 and the Healthy People year 2000 objective	
Figure 27.	Primary and secondary syphilis — Rates by state: United States and outlying areas, 1998	
Figure 28.	Primary and secondary syphilis — Counties with rates above and counties with rates below the Healthy People year 2000 objective: United States, 1998	
Figure 29.	Primary and secondary syphilis — Rates by region: United States, 1981–1998 and the Healthy People year 2000 objective	
Figure 30.	Primary and secondary syphilis — Rates by urban-rural category and geographic region, 1998	
Figure 31.	Primary and secondary syphilis — Rates in selected U.S. Cities of >200,000 population, 1981–1998 and the Healthy People year 2000 objective	
Figure 32.	Primary and secondary syphilis — Rates by gender: United States, 1981–1998 and the Healthy People year 2000 objective	
Figure 33.	Primary and secondary syphilis — Rates by race and ethnicity: United States, 1981–1998 and the Healthy People year 2000 objective 30	
Figure 34.	Primary and secondary syphilis — Age- and gender-specific rates: United States, 1998	
Figure 35.	Congenital syphilis — Reported cases for infants <1 year of age and rates of primary and secondary syphilis among women: United States, 1970–1998	
Figure 36.	Congenital syphilis — Rates for infants <1 year of age: United States, 1981–1998 and the Healthy People year 2000 objective	
Other Sexuall	y Transmitted Diseases	
Figure 37.	Chancroid — Reported cases: United States, 1981–1998	
Figure 38.	Genital herpes simplex virus infections — Initial visits to physicians' offices: United States, 1966–1998 and the Healthy People year 2000 objective	
Figure 39.	Genital herpes simplex virus type 2 — Percent seroprevalence according to age in NHANES* II (1976–1980) and NHANES III (1988–1994) 35	
Figure 40.	Human papillomavirus (genital warts) — Initial visits to physicians' offices: United States, 1966–1998 and the Healthy People year 2000 objective	
Figure 41.	Nonspecific urethritis — Initial visits to physicians' offices by men: United States, 1966–1998	
Figure 42.	Trichomonal and other vaginal infections — Initial visits to physicians' offices: United States, 1966–1998	

# Additional Figures in the Special Focus Profiles

STDs in	Wome	n and Infants	
Figure	A.	Chlamydia — Rates for women by state: United States and outlying areas, 1998	43
Figure	B.	Gonorrhea — Rates for women by state: United States and outlying	43
Figure	C.	Primary and secondary syphilis — Rates for women by state: United States and outlying areas, 1998	44
Figure	D.	Congenital syphilis — Rates for infants <1 year of age by state: United States and outlying areas, 1998	44
Figure	E.	Chlamydia — Positivity among 15-24 year old women tested in prenatal clinics by state, 1998	45
Figure	F.	Gonorrhea — Positivity among 15-24 year old women tested in prenatal clinics by state, 1998	45
Figure	G.	Ectopic pregnancy — Hospitalizations of women 15-44 years of age: United States, 1980-1997	46
Figure	H.	Pelvic inflammatory disease — Hospitalizations of women 15-44 years of age: United States, 1980–1997	46
Figure	I.	Pelvic inflammatory disease — Initial visits to physicians' offices by women 15-44 years of age: United States, 1980–1998 and Healthy People year 2000 objective	47
STDs in	Adole	scents and Young Adults	
Figure	J.	Chlamydia — Positivity among women tested in family planning clinics by age group: Region X, 1988–1998	51
Figure	K.	Chlamydia — Prevalence among 16-24 year-old women entering the	51
Figure	L.	Gonorrhea — Prevalence among 16-24 year-old women entering the	52
Figure	M.	Gonorrhea — Age-specific rates among women 10-44 years of age: United States, 1981–1998	52
Figure	N.	Gonorrhea — Age-specific rates among men 10-44 years of age: United States, 1981–1998	
Figure	O.	Primary and secondary syphilis — Age-specific rates among women 10-44 years of age: United States, 1981–1998	
Figure	P.	Primary and secondary syphilis — Age-specific rates among men 10-44 years of age: United States, 1981–1998	54
STDs in 1	Minor	ities	
Figure	Q.	Chlamydia — Positivity among women tested in family planning clinics by race and ethnicity: Region X, 1988–1998	57
Figure	R.	Gonorrhea — Reported rates for 15-19 year old females by race and ethnicity: United States, 1981–1998	
Figure	S.	Gonorrhea — Reported rates for 15-19 year old males by race and	58
Figure	T.	Primary and secondary syphilis — Reported rates for 15-19 year old	58

Figure U.	Primary and secondary syphilis — Reported rates for 15-19 year old males by race and ethnicity: United States, 1981–1998
Figure V.	Congenital syphilis — Rates for infants <1 year of age by race and ethnicity: United States, 1991–1998
STDs in Perso	ons Entering Corrections Facilities
Figure W.	Syphilis serologic tests — Percent seroreactivity in women entering city or county jails†, 1998
Figure X.	Syphilis serologic tests — Percent seroreactivity in men entering city or county jails <sup>†</sup> , 1998
Figure Y.	Chlamydia — Positivity in women entering juvenile and adult corrections facilities <sup>†</sup> , 1998
Figure Z.	Chlamydia — Positivity in men entering juvenile and adult corrections facilities†, 1998
Figure AA.	Gonorrhea — Positivity in women entering juvenile and adult corrections facilities†, 1998
STDs in the S	outh
Figure BB. Figure CC.	South — Primary and secondary syphilis case rates by county, 1998 67 South — Increases and decreases in cases of primary and secondary syphilis in 1998 compared with 1997 cases, by county 67
Figure DD. Figure EE.	South — Chlamydia case rates by county, 1998
Sources and L	imitations of Data
Figure A1.	Chlamydia — National electronic telecommunications surveillance system (NETSS) transmission status by state, 1998
Figure A2.	Gonorrhea — National electronic telecommunications surveillance system (NETSS) transmission status by state, 1998
Figure A3.	Primary and secondary syphilis — National electronic telecommunications surveillance system (NETSS) transmission status by state, $1998\ldots124$


# **Tables in the National Profile**

National	Sumn	nary Tables	
Table	1.	Cases of sexually transmitted diseases reported by state health departments and rates per 100,000 civilian population: United States, 1941–1998*	69
Table	2.	Reported cases of sexually transmitted disease by gender and reporting source: United States, 1998*	
Chlamyd	ia		
Table	3A.	Chlamydia — Reported cases by age, gender, and race/ethnicity: United States, 1996–1998	72
Table	3B.	Chlamydia — Reported rates per 100,000 population by age, gender, and race/ethnicity: United States, 1996–1998	<b>7</b> 3
Table	4.	Chlamydia — Reported cases and rates by state/area, ranked according to rates: United States and outlying areas, 1998	<b>7</b> 4
Table	5.	Chlamydia — Reported cases and rates by state/area and region: United States and outlying areas, 1994–1998*	<b>7</b> 5
Table	6.	Chlamydia — Women – Reported cases and rates by state/area: United States and outlying areas, 1994–1998*	
Table	7.	Chlamydia — Men – Reported cases and rates by state/area: United States and outlying areas, 1994–1998*	77
Table	8.	Chlamydia — Reported cases and rates in selected cities of >200,000 population, ranked according to rates: United States and outlying	78
Table	9.	Chlamydia — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998*	79
Table 1	10.	Chlamydia — Women – Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994-1998*	80
Table 1	l1.	Chlamydia — Men – Reported cases and rates in selected cities of $>200,\!000$ population: United States and outlying areas, $1994-1998*$ 8	81
Gonorrhe	ea		
Table 1	12A.	Gonorrhea — Reported cases by age, gender, and race/ethnicity: United States, 1994–1998	82
Table 1	2B.	Gonorrhea — Reported rates per 100,000 population by age, gender, and race/ethnicity: United States, 1994–1998	
Table 1	13.	Gonorrhea — Reported cases and rates by state/area, ranked according to rates: United States and outlying areas, 1998	84
Table 1	14.	Gonorrhea — Reported cases and rates by state/area and region: United States and outlying areas, 1994–1998*	85
Table 1	l5.	Gonorrhea — Women – Reported cases and rates by state/area: United States and outlying areas, 1994–1998*	86
Table 1	16.	Gonorrhea — Men – Reported cases and rates by state/area: United States and outlying areas, 1994–1998*	87
Table 1	17.	Gonorrhea — Reported cases and rates in selected cities of >200,000 population, ranked according to rates: United States and outlying	88

Table 18.	Gonorrhea — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998*
Table 19.	Gonorrhea — Women – Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994-1998*90
Table 20.	Gonorrhea — Men – Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998* 91
Syphilis	
Table 21.	All stages of syphilis — Reported cases and rates by state/area: United States and outlying areas, 1994–1998*
Table 22.	All stages of syphilis — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998 93
Table 23A.	Primary and secondary syphilis — Reported cases by age, gender, and race/ethnicity: United States, 1994–199894
Table 23B.	Primary and secondary syphilis — Reported rates by age, gender, and race/ethnicity: United States, 1994–199895
Table 24.	Primary and secondary syphilis — Reported cases and rates by state/area, ranked according to rates: United States and outlying areas, 1998 96
Table 25.	Primary and secondary syphilis — Reported cases and rates by state/area and region: United States and outlying areas, 1994–199897
Table 26.	Primary and secondary syphilis — Women – Reported cases and rates by state/area: United States and outlying areas, 1994–1998
Table 27.	Primary and secondary syphilis — Men – Reported cases and rates by state/area: United States and outlying areas, 1994–199899
Table 28.	Primary and secondary syphilis — Reported cases and rates in selected cities of >200,000 population, ranked according to rates: United States and outlying areas, 1998
Table 29.	Primary and secondary syphilis — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998
Table 30.	Primary and secondary syphilis — Women – Reported cases and rates in selected cities of >200,000 population: United States and outlying
Table 31.	Primary and secondary syphilis — Men – Reported cases and rates in selected cities of >200,000 population: United States and outlying
Table 32.	areas, 1994–1998
Table 33.	Early latent syphilis — Reported cases and rates by state/area: United States and outlying areas, 1994–1998
Table 34.	Early latent syphilis — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998 106
Table 35.	Late and late latent syphilis — Reported cases and rates by state/area: United States and outlying areas, 1994–1998
Table 36.	Late and late latent syphilis — Reported cases and rates in selected cities of >200,000 population: United States and outlying areas, 1994–1998 108
Table 37.	Congenital syphilis — Reported cases and rates in infants <1 year of age: United States (excluding outlying areas), 1963-1998

Table 38.	Congenital syphilis — Reported cases and rates in infants <1 year of age by state/area, ranked according to rates: United States and outlying
Table 39.	areas, 1998
	by state/area: United States and outlying areas, 1994–1998 111
Table 40.	Congenital syphilis — Reported cases and rates in infants <1 year of age in selected cities of >200,000 population, ranked according to rates:  United States and outlying areas, 1998
Table 41.	Congenital syphilis — Reported cases and rates in infants <1 year of age in selected cities of >200,000 population: United States and outlying areas, 1994–1998
Chancroid	
Table 42.	Chancroid — Reported cases and rates by state/area: United States and outlying areas, 1994–1998
Table 43.	Chancroid — Reported cases and rates in selected cities of $>200,000$ population: United States and outlying areas, $1994-1998115$
Appendix	
Table A1.	Healthy People 2000 Sexually Transmitted Diseases Objective 19.1–19.8 Status

# **Geographic Divisions of the United States**



West	Midwest	South	Northeast
Alaska Arizona California Colorado Hawaii	Illinois Indiana Iowa Kansas	Alabama Arkansas Delaware District of Columbia Florida	Connecticut Maine Massachusetts New Hampshire New Jersey
Idaho Montana Nevada New Mexico Oregon Utah	Michigan Minnesota Missouri Nebraska North Dakota Ohio South Dakota	Georgia Kentucky Louisiana Maryland Mississippi North Carolina	New York Pennsylvania Rhode Island Vermont
Washington Wyoming	Wisconsin	Oklahoma South Carolina Tennessee Texas Virginia West Virginia	

## National Overview of Sexually Transmitted Diseases, 1998

The logo on the cover of Sexually Transmitted Disease Surveillance, 1998 is a reminder of the multifaceted, national dimensions of the morbidity, mortality, and costs that result from sexually transmitted diseases (STDs) in the United States. It highlights the central role of STD prevention in improving women's and infants' health and in promoting HIV prevention. Organized collaboration among interested, committed public and private organizations is the key to reducing STDs and their related health burdens in our population. As noted in the recent report of the Institute of Medicine, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*<sup>1</sup>, surveillance is a key component of our efforts to prevent and control these diseases.

This overview summarizes national surveillance data on the three diseases for which we have federally-funded control programs: chlamydia, gonorrhea, and syphilis. Several observations for 1998 are worthy of note.

In 1998, the reported number of cases of genital *Chlamydia trachomatis* infections was 607,602 a rate of 236.6 per 100,000 persons. In 1998, the overall reported rate for women (382.2 per 100,000) was nearly five times that for men (83.1). This difference in reported rates is attributable to screening strategies that focus on women because the severe sequelae of chlamydial infections accrue principally to women, and because these diseases are asymptomatic in the majority of infected women.

Using local, state, and federal resources, chlamydia prevention programs for screening of asymptomatic women have been established throughout the country. In 1998, state-specific chlamydia test positivity among women aged 15-24 years who were screened at family planning clinics ranged from 2.4% to 11.3%. These screening programs have consistently shown that the highest positivity of chlamydial infection in women is in adolescents. In addition, examination of chlamydial screening results for women aged 16-24 years entering the U.S. Job Corps shows that chlamydia is highly prevalent in these economically disadvantaged young women, with state-specific prevalence in 1998 ranging from 4.6% to 20.3%.

In parts of the United States where large-scale chlamydia programs have been instituted, prevalence of disease has generally declined. During 1988-1998, among 15- to 44-year-old women participating in the screening programs in Health and Human Services (HHS) Region X family planning clinics, chlamydia test positivity declined 60% (from 9.3% to 3.7%). During 1994-1998, among women under 45 years of age in Region III, positivity declined 6.4% (from 4.7% to 4.4%), and in Region VIII, positivity declined 10.3% (from 3.9% to 3.5%). Adjustment for changes in laboratory test method and sensitivity in 1998 may demonstrate larger declines in these and other HHS regions. For definition of HHS regions, see the Appendix.

Recent data on gonorrhea for 1994-1998 suggest that the annual decreases that have generally been evident since the national gonorrhea control program began in the mid-1970s may be lessening. In particular, the gonorrhea rate for 1998 (132.9 per 100,000 persons) was greater than the rate for 1997 (122.0). Although the 1997 gonorrhea rate was the lowest rate since national reporting

STD Surveillance 1998 Overview 1

began, both it and the 1998 rate remain well above the revised Healthy People 2000 (HP2000) objective of 100.

With respect to gender, the gonorrhea rates for males and for females increased between 1997 and 1998. The gonorrhea rate for males increased from 124.9 to 133.7, and for females increased from 119.0 to 131.5. In contrast to earlier years, which generally exhibited decreasing age-specific rates for gonorrhea, most 5 year age categories had rates which increased between 1997 and 1998. These increases ranged from 6% to 14%. Only the rate for the oldest adults decreased slightly. Because men with gonorrhea are often symptomatic and seek medical care, trends in males are probably a good measure of trends in disease incidence. Trends in women are determined more by screening practices. Similar to chlamydia, rates of gonorrhea in women are particularly high in adolescents, with the highest rates in 15- to 19-year-olds.

With regard to antimicrobial resistance, a small proportion of *Neisseria gonorrhoeae* isolates tested through the Gonococcal Isolate Surveillance Project in 1998 (0.9%) demonstrated decreased susceptibility to ciprofloxacin, one of the currently recommended treatments for gonorrhea. However, resistance to ciprofloxacin continued to be rare (0.1%).

The 6,993 cases of primary and secondary (P&S) syphilis reported in 1998 were the fewest cases reported in the United States since 1958. The P&S syphilis rate of 2.6 per 100,000 persons (the lowest since national reporting began in 1941) is below the HP2000 objective of 4 per 100,000. Syphilis continues to be reported only in specific areas of the country. In 1998, approximately 78% of U.S. counties reported no cases of P&S syphilis. However, P&S syphilis rates exceeded 4 per 100,000 in 312 counties (10% of total counties). These 312 counties accounted for 76% of all reported P&S syphilis cases. Most notably, 91% (285 of 312) of these counties were in the South. In addition, 9 of the 12 states or outlying areas with P&S syphilis rates greater than 4 per 100,000 were located in the South. These data suggest that comprehensive syphilis prevention efforts focused in the South could markedly reduce the number of U.S. syphilis cases.

When STD statistics were examined by race or ethnicity, wide discrepancies in reported STD rates persisted between racial or ethnic groups. For example, the gonorrhea rate in blacks is approximately 30 times greater than the rate in whites. The rate of P&S syphilis in blacks is about 34 times that in whites; P&S syphilis in Hispanics is about 3 times that in whites. However, in 1998, of the 793 reported congenital syphilis cases with known race or ethnicity of the mother, blacks and Hispanics accounted for 89% of these reported cases, while accounting for only 23% of the female population, and 33% of all births. Race and ethnicity in the United States serve as risk markers that correlate with other, more fundamental determinants of health status such as socioeconomic status and access to good quality medical care. Reporting biases also undoubtedly play a role in race differentials, while not explaining them completely.

2 Overview STD Surveillance 1998

<sup>&</sup>lt;sup>1</sup>Institute of Medicine. *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, Committee on Prevention and Control of Sexually Transmitted Diseases, National Academy Press, Washington, D.C., 1997.